Cost-effectiveness of direct-acting antivirals (DAAs) compared to pegylated interferon (PegIFN) with ribavirin (RBV) in previously untreated hepatitis C virus genotype 1 (GT1) infected patients without advanced liver disease in Hong Kong

Abstract